专利检索 ap:("TUFTS UNIVERSITY" OR "Philip G. Haydon" OR "Jinbo Lee") AND inv:"Jinbo Lee" 第 1 页

1.

发明授权
Uridine nucleoside derivatives, compositions and methods of use 有权

公开(公告)号：US10544183B2

公开(公告)日：2020-01-28

申请号：US14775426

申请日：2014-03-13

申请人： TUFTS UNIVERSITY , Philip G. Haydon , Jinbo Lee

发明人： Philip G. Haydon , Jinbo Lee

IPC分类号： A61K31/7064 , A61K31/7068 , A61K31/7072 , C07H19/06

摘要： This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.

2.

发明申请
URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：尿苷核苷衍生物，组合物和使用方法

公开(公告)号：US20160075731A1

公开(公告)日：2016-03-17

申请号：US14775426

申请日：2014-03-13

申请人： Philip G. HAYDON , Jinbo LEE , TUFTS UNIVERSITY

发明人： Philip G. Haydon , Jinbo Lee

IPC分类号： C07H19/06

摘要： This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.

摘要翻译： 本公开涉及尿苷核苷衍生物，包含治疗有效量的那些核苷衍生物的组合物和使用这些核苷衍生物或组合物治疗对P2Y6受体的配体如激动剂例如神经元障碍（包括神经变性）起反应的疾病的方法疾病（如阿尔茨海默病，帕金森病）和外伤性CNS损伤，疼痛，唐氏综合征（DS），青光眼和炎症状况。

3.

发明申请
HALOFUGINONE ANALOGS FOR INHIBITION OF TRNA SYNTHETASES AND USES THEREOF 有权
标题翻译：用于抑制TRNA合成的HOFOFGGONEONE模拟物及其用途

公开(公告)号：US20110263532A1

公开(公告)日：2011-10-27

申请号：US13058486

申请日：2009-08-11

申请人： Tracy Keller , Ralph Mazitschek , Malcolm Whitman , Jinbo Lee

发明人： Tracy Keller , Ralph Mazitschek , Malcolm Whitman , Jinbo Lee

IPC分类号： A61K31/675 , A61K31/517 , C07F7/10 , A61K31/695 , C07D401/14 , C07D413/14 , A61K31/5377 , C07D487/04 , A61K31/519 , C07D495/04 , C07F9/6558 , C07D405/14 , A61P37/06 , A61P35/00 , A61P29/02 , A61P33/02 , A61P43/00 , C07D401/12

CPC分类号： A61K31/4184 , A61K31/685 , A61K31/695 , C07D401/06 , C07D401/14 , C07D403/06 , C07D405/14 , C07D491/04 , C07D495/04 , C07F9/65583

摘要： The present invention provides novel analogs and derivatives of halofuginone. The invention also provides pharmaceutical and cosmetic compositions thereof and methods for using halofuginone analogs in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, ischemic damage, transplant and implant rejection, neurodegenerative diseases, and cosmetic applications.

摘要翻译： 本发明提供卤代酮的新型类似物和衍生物。本发明还提供其药物和化妆品组合物以及使用卤夫酮类似物治疗慢性炎性疾病，自身免疫性疾病，干眼综合症，纤维化，瘢痕形成，血管生成，病毒感染，缺血性损伤，移植和植入物排斥，神经变性疾病和化妆品应用。

4.

发明授权
11-beta HSD1 inhibitors 失效
标题翻译： 11-beta HSD1抑制剂

公开(公告)号：US07632838B2

公开(公告)日：2009-12-15

申请号：US11703522

申请日：2007-02-07

申请人： Jason Shaoyun Xiang , Eddine Saiah , Steve Y. Tam , John C. Mckew , Lihren Chen , Manus Ipek , Huan-Qiu Li , Jianchang Li , Wei Li , Tarek Suhayl Mansour , Vipin Suri , Yuchuan Wu , Zhao-Kui Wan , Jinbo Lee , Eva Binnun , Douglas P. Wilson

发明人： Jason Shaoyun Xiang , Eddine Saiah , Steve Y. Tam , John C. Mckew , Lihren Chen , Manus Ipek , Huan-Qiu Li , Jianchang Li , Wei Li , Tarek Suhayl Mansour , Vipin Suri , Yuchuan Wu , Zhao-Kui Wan , Jinbo Lee , Eva Binnun , Douglas P. Wilson

IPC分类号： A61K31/4965 , C07D241/04 , C07D295/00

CPC分类号： C07D211/96 , C07D295/26 , C07D401/04 , C07D403/02 , C07D409/02 , C07D413/02

摘要： This invention relates to inhibiting 11βHSD1.

摘要翻译： 本发明涉及抑制11betaHSD1。

5.

发明申请
Inhibitors of protein tyrosine phosphatase 1B 失效
标题翻译：蛋白酪氨酸磷酸酶1B抑制剂

公开(公告)号：US20050203087A1

公开(公告)日：2005-09-15

申请号：US11063475

申请日：2005-02-23

申请人： Jinbo Lee , Zhao-Kui Wan , Douglas Wilson , Bruce Follows , Steven Kirincich , Michael Smith , Jun-Jun Wu , Kenneth Foreman , David Erbe , Yan-Ling Zhang , Weixin Xu , Steve Tam

发明人： Jinbo Lee , Zhao-Kui Wan , Douglas Wilson , Bruce Follows , Steven Kirincich , Michael Smith , Jun-Jun Wu , Kenneth Foreman , David Erbe , Yan-Ling Zhang , Weixin Xu , Steve Tam

IPC分类号： A61K31/381 , A61K31/4025 , A61K31/4178 , A61K31/453 , A61K31/496 , A61K31/5377 , A61K31/541

CPC分类号： C07D333/38 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D451/02

摘要： Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted thiophene compounds such as, for example, 2-carboxyl, 3-carboxymethoxy, 5-aryl substituted thiophenes, can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.

摘要翻译： 蛋白酪氨酸磷酸酶（PTPases）如PTP1B可以在调节各种细胞反应（如胰岛素信号）中发挥作用。取代的噻吩化合物例如2-羧基，3-羧基甲氧基，5-芳基取代的噻吩可以抑制PTP1B，从而诱导更大的胰岛素敏感性。因此，PTP1B抑制可以为PTPase介导的病症例如糖尿病提供替代治疗。

6.

发明授权
Substituted benzimidazole compounds 有权
标题翻译：取代的苯并咪唑化合物

公开(公告)号：US06825219B2

公开(公告)日：2004-11-30

申请号：US10288362

申请日：2002-11-05

申请人： Charles Cywin , Jinbo Lee , Steven S. Pullen , Gregory Paul Roth , Christopher Ronald Sarko , Roger John Snow , Noel Stewart Wilson

发明人： Charles Cywin , Jinbo Lee , Steven S. Pullen , Gregory Paul Roth , Christopher Ronald Sarko , Roger John Snow , Noel Stewart Wilson

IPC分类号： A61K314184

CPC分类号： C07D401/12 , C07D235/30 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12

摘要： Disclosed are substituted benzimidazole compounds of formula(I): wherein R1, R2, R3, R4 and Xa are defined herein. The compounds of the invention are useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.

摘要翻译： 公开了式（I）的取代的苯并咪唑化合物：其中R1，R2，R3，R4和Xa在本文中定义。本发明的化合物可用于治疗涉及炎症，免疫学障碍和过敏性疾病的疾病和病理状况。还公开了制备这些化合物的方法和包含这些化合物的药物组合物。

7.

发明申请
MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA 失效
标题翻译：用于抑制肿瘤坏死因子ALPHA的大环化合物

公开(公告)号：US20100152099A1

公开(公告)日：2010-06-17

申请号：US12544604

申请日：2009-08-20

申请人： Jinbo Lee , Julian F. Bond , Nicholas Terrett , Frank G. Favaloro, JR. , Daniel Wang , Timothy F. Briggs , Benjamin A. Seigal , Wei-Chuan Sun , Stephen P. Hale

发明人： Jinbo Lee , Julian F. Bond , Nicholas Terrett , Frank G. Favaloro, JR. , Daniel Wang , Timothy F. Briggs , Benjamin A. Seigal , Wei-Chuan Sun , Stephen P. Hale

IPC分类号： A61K38/12 , C07K5/12 , A61P19/02 , A61P1/00 , A61P35/00 , A61P3/10 , A61P25/28

CPC分类号： C07D273/00 , C07D257/02

摘要： The invention provides macrocyclic compounds and methods for their synthesis and use. In particular, the invention provides macrocyclic compounds that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma.

摘要翻译： 本发明提供了大环化合物及其合成和使用方法。特别地，本发明提供调节肿瘤坏死因子α活性的大环化合物和/或可用于治疗诸如类风湿性关节炎，牛皮癣和哮喘的医学病症。

8.

发明授权
Inhibitors of protein tyrosine phosphatase 1B 失效
标题翻译：蛋白酪氨酸磷酸酶1B抑制剂

公开(公告)号：US07521473B2

公开(公告)日：2009-04-21

申请号：US11063475

申请日：2005-02-23

申请人： Jinbo Lee , Zhao-Kui Wan , Douglas P. Wilson , Bruce C. Follows , Steven J. Kirincich , Michael J. Smith , Jun-Jun Wu , Kenneth W. Foreman , David V. Erbe , Yan-Ling Zhang , Weixin Xu , Steve Y. Tam

发明人： Jinbo Lee , Zhao-Kui Wan , Douglas P. Wilson , Bruce C. Follows , Steven J. Kirincich , Michael J. Smith , Jun-Jun Wu , Kenneth W. Foreman , David V. Erbe , Yan-Ling Zhang , Weixin Xu , Steve Y. Tam

IPC分类号： A61K31/381 , C07D333/38

CPC分类号： C07D333/38 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D451/02

摘要： Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted thiophene compounds such as, for example, 2-carboxyl, 3-carboxymethoxy, 5-aryl substituted thiophenes, can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.

摘要翻译： 蛋白酪氨酸磷酸酶（PTPases）如PTP1B可以在调节各种细胞反应（如胰岛素信号）中发挥作用。取代的噻吩化合物例如2-羧基，3-羧基甲氧基，5-芳基取代的噻吩可以抑制PTP1B，从而诱导更大的胰岛素敏感性。因此，PTP1B抑制可以为PTPase介导的病症例如糖尿病提供替代治疗。

9.

发明申请
PTP1B inhibitors 审中-公开
标题翻译： PTP1B抑制剂

公开(公告)号：US20080004325A1

公开(公告)日：2008-01-03

申请号：US11824007

申请日：2007-06-29

申请人： Jinbo Lee , Zhao-Kui Wan , Douglas P. Wilson , Eva Binnun , David V. Erbe , Eddine Saiah

发明人： Jinbo Lee , Zhao-Kui Wan , Douglas P. Wilson , Eva Binnun , David V. Erbe , Eddine Saiah

IPC分类号： A61K31/433 , C07D417/04

CPC分类号： C07D417/04

摘要： This invention relates to modulating (e.g., inhibiting) protein tyrosine phosphatase 1b (PTP1b).

摘要翻译： 本发明涉及调节（例如抑制）蛋白酪氨酸磷酸酶1b（PTP1b）。